Even the most aggressive treatment with statin drugs fails to prevent coronary artery disease.

Two research presented at the American University of Cardiology’s 56th Annual Scientific Session assessed the effects of adding torcetrapib to atorvastatin among individuals to boost their cholesterol levels. Although the ILLUMINATE research and various other trials involving torcetrapib were stopped due to safety concerns recently, the result of the drug on carotid intima-press thickness may provide useful information on whether it slows the progression of atherosclerosis.AATS is certainly developing its next set of recommendations currently, like the AATS risk calculator, slated for discharge in 2014. 28-31 What:ASTRO’s Annual Meeting is the premier scientific meeting in radiation oncology and is definitely expected to attract a lot more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, doctor assistants, practice administrators, sector representatives and other health care specialists from around the global globe.

Copyright blindserver.com 2017